Benzodiazepines for Anxiety: Benefits, Risks and What the Evidence Shows

Benzodiazepines are one of the most effective short-term treatments for anxiety and one of the most problematic long-term ones. Understanding both sides of this equation is important for anyone using, considering, or trying to stop these medications.

How they work

Benzodiazepines (diazepam, alprazolam, lorazepam, clonazepam and others) enhance the effect of GABA, the brain’s primary inhibitory neurotransmitter, at GABA-A receptors. The result is rapid reduction in anxiety, muscle relaxation, sedation and anticonvulsant effects. Onset is fast — often within 30–60 minutes for oral dosing.

This speed is their primary clinical advantage. SSRIs take weeks to reach full effect. CBT takes weeks of practice. Benzodiazepines work today.

Short-term efficacy

In controlled trials, benzodiazepines consistently outperform placebo for acute anxiety, with moderate-to-large effect sizes [1]. For short-term use (days to weeks), the evidence of benefit is clear. They are particularly effective for acute panic, procedural anxiety and brief situational anxiety.

The clinical challenge is that anxiety disorders are usually not brief situations. GAD is chronic. Panic disorder recurs. Social anxiety persists. The treatment that works fastest is the treatment most likely to become a long-term problem.

The dependence problem

Physical dependence can develop within 2–4 weeks of daily use [2]. The mechanism involves neuroadaptation: GABA receptors downregulate in response to constant benzodiazepine exposure, meaning the same dose produces less effect (tolerance) and stopping produces a rebound of anxiety and arousal that can be worse than the original problem (withdrawal).

Withdrawal symptoms include anxiety (often worse than pre-treatment), insomnia, tremor, sweating, muscle pain and perceptual disturbances. Abrupt withdrawal from high doses can cause seizures, which is a medical emergency. Gradual tapering over weeks to months is the standard approach, but even gradual withdrawal is often difficult and protracted [6].

Short-acting benzodiazepines (alprazolam) may carry higher dependence risk because blood levels fluctuate more, creating frequent mini-withdrawals that reinforce use. This pharmacokinetic argument is supported by some clinical data, though not all clinicians agree [2].

Cognitive effects

A meta-analysis of cognitive effects in long-term benzodiazepine users found consistent impairments across memory, attention, processing speed and visuospatial ability [3]. These deficits were present even after controlling for anxiety and depression.

The recovery question is important and only partially answered. Some studies find that cognitive function improves after benzodiazepine discontinuation, but the recovery may be incomplete, particularly in older adults. Whether long-term use causes permanent cognitive damage or whether the impairments are fully reversible is debated. The observational nature of most evidence makes it difficult to separate the drug’s effects from the effects of chronic anxiety itself.

What guidelines say

NICE recommends that benzodiazepines should not be offered for the treatment of GAD or panic disorder except as a short-term measure during crises, and only for a maximum of 2–4 weeks [5]. Similar guidance exists from most international bodies.

Despite this, long-term prescribing remains common. A substantial number of patients have been on benzodiazepines for years or decades. This reflects a combination of factors: the medications work, alternatives are not always effective or accessible, and deprescribing is genuinely difficult for patients who are physically dependent.

Deprescribing challenges

A Cochrane review of interventions to help people stop benzodiazepines found that gradual dose reduction combined with psychological support was modestly effective, but relapse rates were high [4]. Many patients who successfully taper experience protracted withdrawal symptoms lasting months.

This creates a clinical dilemma: continuing carries risks, but stopping is distressing and not always successful. The pragmatic approach for long-term users is usually very gradual tapering (months, not weeks) with psychological support, but even this doesn’t work for everyone.

Questions to ask about benzodiazepine use

1. Is this for short-term use (days to weeks) or potentially longer?
2. Have first-line treatments (CBT, SSRIs) been tried or considered?
3. What is the plan for stopping?
4. Are there specific risk factors (older age, history of substance use, respiratory conditions)?
5. If currently taking long-term, is gradual reduction feasible?

What remains uncertain

Whether very low-dose, intermittent use (e.g., one dose before a flight) carries the same risks as regular daily use is not well studied. Whether newer formulations or delivery methods could reduce dependence risk while preserving efficacy is an active area of drug development. Whether the cognitive effects of long-term use are genuinely permanent or fully reversible needs better longitudinal evidence.

If you take benzodiazepines. Do not stop or reduce benzodiazepines abruptly — withdrawal can be dangerous. Any changes should be made with your prescriber’s guidance, usually through very gradual reduction. If you’re concerned about dependence, talk to your doctor about a tapering plan. If anxiety is affecting your daily life, talk to a GP or mental health professional. If you are in crisis or thinking about harming yourself, contact emergency services or a crisis line now: in the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.